Navigation Links
Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
Date:3/9/2009

WALTHAM, Mass., March 9 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the Cowen and Company 29th Annual Healthcare Conference on Monday, March 16th, 2009 at 2:25 p.m. EDT at the Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA. A live audio webcast of the presentation will be available via Repligen's website at www.repligen.com and will be archived for 30 days following the presentation.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product deve
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
2. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
3. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
4. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
5. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
8. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
9. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
10. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
11. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: ... areas, announced the closing of an underwritten public offering of ... to an aggregate 3,500,000 shares of common stock, at an ... The warrants have a per share exercise price of $5.00, ...
(Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
(Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Products Industry Leader, DEERFIELD, Ill., Sept. 12 ... it has been named 2007,Medical Products Industry Leader of ... Dow Jones Sustainability North America Index,(DJSI North America). This ... listed in the DJSI and the sixth year the ...
... 12 Leading scientists,from around the world will ... approaches for producing life-saving vaccines and,antibodies. More than ... "New Cells for New Vaccines II: Focus on ... du Pont. The international,scientific workshop is being organized ...
... 12 Human Pheromone,Sciences, Inc. (OTC Bulletin Board: ... of an exclusive Agency Agreement with Brand,Intelligence Group, ... Attraction(R) brand, which contains its proprietary and patented,human ... Agreement, HPS and BIG will work together to,develop ...
Cached Biology Technology:Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year 2International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development 2Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand 2
(Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
(Date:12/19/2014)... Inc., the leading personal genetics company, today announced the publication ... of individuals from across the United States ... hundred years ago, the United States ... continents. This study illuminates how American history and the ongoing ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Discovery Fund (LSDF) today announced $1.1 million in ... and non-profit organizations to foster the translation of ... marketplace. Two of the five new ... invented within Washington-based companies. HeatFlow Technologies (principal investigator ...
... Researchers at Queen Mary University of London have shown for ... on to perform is controlled by primary cilia tiny hair-like ... of becoming any cell type within the body through the ... for application in the development of new therapies for a ...
... has known for years that people who drink moderate amounts ... general, they are healthier and have better cardiovascular function that ... research from Oregon Health & Science University adds a fascinating ... help it fight off infection. The research, published Dec. ...
Cached Biology News:Life Sciences Discovery Fund announces R&D grants 2Study: Moderate alcohol consumption boosts body's immune system 2Study: Moderate alcohol consumption boosts body's immune system 3
...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Antibody Diluent for IHC 125 ml...
QPRT Antibody...
Biology Products: